International Clinical Trial: Shenzhen Waldenstrom Macroglobulinemia Multicenter Real-world Study: Molecular Characteristics, Treatment Modalities and Clinical Decision Optimization

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119152) titled 'Shenzhen Waldenstrom Macroglobulinemia Multicenter Real-world Study: Molecular Characteristics, Treatment Modalities and Clinical Decision Optimization' on Feb. 24.

Study Type: Observational study

Study Design: Sequential

Primary Sponsor: Peking University Shenzhen Hospital

Condition: Waldenstrom's Macroglobulinemia

Intervention: Group 3(Genotype Unknown):None Group 1(MYD88 Wild-Type):None

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-03-02

Target Sample Size: Group 3(Genotype Unknown):16;Group 1(MYD88 Wild-Type):17;Group 2 (CXCR4 Mutant):17;

Countries of Recruitmen...